| Literature DB >> 33003632 |
Guillermo López-Díaz1, Almudena Rodríguez-Fernández2, Eva María Domínguez-Martís3, Diego Gabriel Mosteiro-Miguéns1, David López-Ares4, Silvia Novío2.
Abstract
Human immunodeficiency virus (HIV) infection is one of the main causes of morbidity and mortality worldwide. Among the preventive approaches proposed to control this disease is pre-exposure prophylaxis (PrEP), whose effectiveness depends on the medication adherence. The aim of the present study was to determine the knowledge and attitudes about PrEP among a sample of Spanish nursing students as well as their intentions of receiving it in case it was indicated. An observational cross-sectional descriptive study was carried out. A total of 570 nursing students from the University of Santiago de Compostela (Spain), ≥18 years old and of both sexes were invited to self-complete a questionnaire between February and March 2020. A total of 352 students decided to participate in the study. Participants had low knowledge [overall knowledge score 1(0-2)] and a neutral attitude towards PrEP. The intention of receiving PrEP improved significantly after the completion of the questionnaire and the administration of information about PrEP (p = 0.039; before: 23.58% and after: 93.77%). Nursing staff play an important role in the prevention of sexually transmitted diseases, so their training in preventive strategies, such as PrEP, could help to reduce the incidence of new cases of HIV infection.Entities:
Keywords: HIV; attitude; intention; knowledge; nursing; pre-exposure prophylaxis
Mesh:
Substances:
Year: 2020 PMID: 33003632 PMCID: PMC7578937 DOI: 10.3390/ijerph17197151
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Sociodemographic characteristics and other personal data of the study’s participants.
| All Students | First Year | Second Year | Third Year | Fourth Year | |
|---|---|---|---|---|---|
| N = 131 | N = 96 | N = 71 | N = 54 | ||
| N = 352 | (37.22%) | (27.27%) | (20.17%) | (15.34%) | |
| Age (years), M (SD) and Med (IQR) | 20.4 (3.62) | 18.7 (1.2) | 20.8 (3.7) | 21.3 (2.8) | 22.7 (2.3) |
| 20 (19–21) | 18 (18–19) | 19 (19–20) | 20 (20–21) | 21 (21–22.3) | |
| Sex, | |||||
| Male | 44 (12.5) | 17 (12.98) | 10 (10.42) | 10 (14.08) | 7 (12.96) |
| Female | 308 (87.5) | 114 (87.02) | 86 (89.58) | 61 (85.92) | 47 (87.04) |
| Practice area considered, | |||||
| Community nursing | 59 (16.76) | 6 (4.58) | 18 (18.75) | 20 (28.17) | 15 (27.78) |
| Surgical-medical nursing | 83 (23.58) | 45 (34.35) | 20 (20.83) | 10 (14.08) | 8 (14.81) |
| Pediatric nursing | 132 (37.5) | 55 (41.98) | 33 (34.38) | 27 (38.03) | 17 (31.48) |
| Emergency, ICU and RU | 159 (45.17) | 60 (45.8) | 39 (40.62) | 26 (36.62) | 34 (62.96) |
| Obstetric-gynecologic nursing | 118 (33.52) | 42 (32.06) | 33 (34.38) | 23 (32.39) | 20 (37.04) |
| Mental health nursing | 52 (14.77) | 20 (15.27) | 10 (10.42) | 12 (16.9) | 10 (18.52) |
| Occupational nursing | 4 (1.14) | 0 | 1 (1.04) | 1 (1.41) | 2 (3.7) |
| Geriatric nursing | 16 (4.55) | 5 (3.82) | 4 (4.17) | 5 (7.04) | 2 (3.7) |
| Other | 4 (1.14) | 2 (1.53) | 0 | 2 (2.82) | 0 |
| I have not decided yet | 86 (24.43) | 37 (28.24) | 23 (23.96) | 16 (22.54) | 10 (18.52) |
| Have you done any research or received any training on HIV in your nursing degree?, n (%) | |||||
| Yes | 136 (38.64) | 8 (6.11) | 65 (67.71) | 31 (43.66) | 32 (59.26) |
| No | 196 (55.68) | 119 (90.84) | 27 (28.12) | 32 (45.07) | 18 (33.33) |
| DK/NO | 20 (5.68) | 4 (3.05) | 4 (4.17) | 8 (11.27) | 4 (7.41) |
| Have you ever heard of PrEP?, | |||||
| Yes | 52 (14.77) | 11 (8.4) | 20 (20.83) | 9 (12.68) | 12 (22.22) |
| No | 293 (83.24) | 119 (90.84) | 72 (75.00) | 60 (84.51) | 42 (77.78) |
| DK/NO | 7 (1.99) | 1 (0.76) | 4 (4.17) | 2 (2.82) | 0 |
| Source of information about PrEP, | |||||
| Training programme in the nursing degree | 24 (46.21) | 3 (5.77) | 11 (21.15) | 4 (7.69) | 6 (11.54) |
| Healthcare professionals | 11 (21.15) | 3 (5.77) | 2 (3.85) | 3 (5.77) | 3 (5.77) |
| Clinical practice guidelines | 6 (11.54) | 1 (1.92) | 1 (1.92) | 2 (3.85) | 2 (3.85) |
| Relatives or friends | 7 (13.46) | 2 (3.85) | 1 (1.92) | 3 (5.77) | 1 (1.92) |
| Traditional communication media | 15 (28.85) | 5 (9.62) | 8 (15.38) | 1 (1.92) | 1 (1.92) |
| Social networkings | 26 (50) | 8 (15.38) | 8 (15.38) | 6 (11.54) | 4 (7.69) |
| Other | 7 (13.46) | 3 (5.77) | 2 (3.85) | 1 (1.92) | 1 (1.92) |
| As healthcare professional, would you ask your patients about their sexual orientation?, | |||||
| Yes | 49 (13.92) | 15 (11.45) | 15 (15.62) | 12 (16.9) | 7 (12.96) |
| No | 245 (69.6) | 92 (70.23) | 66 (68.75) | 49 (69.01) | 38 (70.37) |
| DK/NO | 58 (16.48) | 24 (18.32) | 15 (15.62) | 10 (14.08) | 9 (16.67) |
| As healthcare professional, would you ask your patients about their sexual risk behaviors?, | |||||
| Yes | 302 (85.8) | 117 (89.31) | 78 (81.25) | 61 (85.92) | 46 (85.19) |
| No | 22 (6.25) | 6 (4.58) | 7 (7.29) | 6 (8.45) | 3 (5.56) |
| DK/NO | 28 (7.95) | 8 (6.11) | 11 (11.46) | 4 (5.63) | 5 (9.26) |
| According to your knowledge, if you belonged to a population group at high risk for HIV infection, would you be willing to receive PrEP?, | |||||
| Yes | 83 (23.58) | 25 (19.08) | 27 (28.12) | 18 (25.35) | 13 (24.07) |
| No | 29 (8.24) | 12 (9.16) | 3 (3.12) | 7 (9.86) | 7 (12.96) |
| DK/NO | 240 (68.18) | 94 (71.76%) | 66 (68.75) | 46 (64.79) | 34 (62.96) |
Abbreviations: DK/NO. Do not know/no opinion; HIV. Human immunodeficiency virus; ICU. Intensive Care Unit; IQR. Interquartile range; M. Mean; Med. Median; RU. Reanimation Unit; SD. Standard deviation.
Knowledge of pre-exposure prophylaxis (PrEP).
| All Students |
| |
|---|---|---|
| N = 352 | ||
| Q11. The antiretroviral drugs used for PrEP approved by the FDA are: | ||
| Lopinavir (Kaletra®) | 2 (0.57) | <0.05 |
|
| 12 (3.41) | |
| Emtricitabine + tenofovir + efavirenz (Atripla®) | 9 (2.56) | |
| DK/NO | 329 (93.47) | |
| Q12. The PrEP is administered by: | ||
| Intravenous route | 6 (1.7) | >0.05 |
| Subcutaneous route | 3 (0.85) | |
| Intramuscular route | 1 (0.28) | |
|
| 66 (18.75) | |
| DK/NO | 276 (78.41) | |
| Q13. According to the FDA, the antiretroviral drugs used for PrEP must be taken: | ||
|
| 44 (12.50) | <0.05 |
| Weekly | 2 (0.57) | |
| Before sexual intercourse | 10 (2.84) | |
| After sexual intercourse | 6 (1.70) | |
| DK/NO | 290 (82.39) | |
| Q14. PrEP is contraindicated in patients with: | ||
|
| 10 (2.84) | <0.05 |
| History of myocardial infarction | 2 (0.85) | |
| Hypertension | 7 (1.99) | |
| DK/NO | 329 (93.47) | |
| Q15. Asymptomatic people must have an HIV test before starting PrEP: | ||
|
| 119 (33.81) | <0.05 |
| No | 20 (5.68) | |
| DK/NO | 213 (60.51) | |
| Q16. STDs must be ruled out before starting PrEP: | ||
|
| 150 (42.61) | >0.05 |
| No | 4 (1.14) | |
| DK/NO | 198 (56.25) | |
| Q17. While taking PrEP, people must have regular clinical and analytical follow-up visits with the healthcare provider every: | ||
| Week | 7 (1.99) | <0.05 |
| Month | 23 (6.53) | |
|
| 32 (9.09) | |
| Year | 4 (1.14) | |
| DK/NO | 286 (81.25) | |
| Q18. PrEP reduces the risk of getting HIV and other STDs: | ||
| Yes | 25 (7.10) | <0.05 |
|
| 48 (13.64) | |
| DK/NO | 279 (79.26) | |
| Overall knowledge score | 1 (0-2) | <0.05 |
The correct answers have been underlined. The answers were compared according to the sex, age, class year and prior training or knowledge of HIV/AIDS and PrEP. Statistical significance (p < 0.05) was determined by chi-square test (questions 11–18) and Kruskal-Wallis and Mann-Whitney U tests (overall knowledge score). Abbreviations: DK/NO. Do not know/no opinion; FDA. Food and Drug Administration; HIV. Human immunodeficiency virus; PrEP. Pre-exposure prophylaxis; Q. Question; STDs. Sexually transmitted diseases.
Attitudes towards pre-exposure prophylaxis (PrEP).
| Total | Mean (SD) |
| ||||||
|---|---|---|---|---|---|---|---|---|
| N = 352 | ||||||||
| 1 | 2 | 3 | 4 | 5 | ||||
| Q19. There is insufficient evidence at this time to consider PrEP an appropriate prevention strategy | 17 (4.83) | 35 (9.94) | 251 (71.31) | 40 (11.36) | 9(2.56) | 2.97 (0.71) | <0.05 | |
| Q20. PrEP is a cost-effective HIV prevention intervention if used with an appropriate population of patients | 2 (0.57) | 11 (3.12) | 230 (65.34) | 93 (26.42) | 16 (4.55) | 3.31 (0.64) | <0.05 | |
| Q21. PrEP will cause people to have more risky sex | 19 (5.4) | 75 (21.31) | 148 (42.05) | 91 (25.85) | 19(5.4) | 3.05 (0.95) | <0.05 | |
| Q22. People with very high risk of HIV infection must be encouraged to use condoms rather than to take PrEP | 7 (1.99) | 35 (9.94) | 170 (48.3) | 91 (25.85) | 49 (13.92) | 3.4 (0.92) | >0.05 | |
| Q23. PrEP may be given preference over other preventive strategies | 16 (4.55) | 69 (19.6) | 203 (57.67) | 57 (16.19) | 7(1.99) | 2.91 (0.78) | >0.05 | |
| Q24. Widespread use of PrEP will likely significantly increase rates of antiretroviral resistance | 2 (0.57) | 23 (6.53) | 232 (65.91) | 82 (23.3) | 13 (3.69) | 3.23 (0.65) | >0.05 | |
| Q25. PrEP is associated to important side effects | 3 (0.85) | 24 (6.82) | 302 (85.8) | 19 (5.4) | 4(1.14) | 2.99 (0.45) | <0.05 | |
| Q26. PrEP adherence is critical to efficacy | 2 (0.57) | 8(2.27) | 219 (62.22) | 83 (23.58) | 40 (11.36) | 3.43 (0.74) | <0.05 | |
| Q27. Nurses play an important role in prevention of sexual risk behaviors and STDs, such as HIV, through patient education | 2 (0.57) | 3 (0.85) | 33 (9.38) | 52 (14.77) | 262 (74.43) | 4.62 (0.74) | >0.05 | |
| Q28. It is neccessary to allocate resources for PrEP research | 2 (0.57) | 4 (1.14) | 87 (24.72) | 144 (40.91) | 115 (32.67) | 4.04 (0.82) | <0.05 | |
| Q29. PrEP must be paid by the patient | 69 (19.6) | 110 (31.25) | 156 (44.32) | 12 (3.41) | 5 (1.42) | 2.36 (0.88) | >0.05 | |
| Q30. PrEP must be financed by the Social Security System | 3 (0.85) | 12 (3.41) | 140 (39.77) | 125 (35.51) | 72 (20.45) | 3.71 (0.86) | >0.05 | |
| Q31. PrEP is recommended for: | ||||||||
| a. Men who have sex with men | 11 (3.12) | 9 (2.56) | 134 (38.07) | 107 (30.4) | 91 (25.85) | 3.73 (0.98) | <0.05 | |
| b. Heterosexual people | 9 (2.56) | 12 (3.41) | 145 (41.19) | 101 (28.69) | 85 (24.15) | 3.68 (0.96) | <0.05 | |
| c. Transgender people | 10 (2.84) | 10 (2.84) | 161 (45.74) | 86 (24.43) | 85 (24.15) | 3.64 (0.97) | <0.05 | |
| d. Sex workers | 6 (1.7) | 9 (2.56) | 115 (32.67) | 108 (30.68) | 114 (32.39) | 3.89 (0.95) | <0.05 | |
| e. People with multiple sex partners | 7 (1.99) | 6 (1.7) | 120 (34.09) | 109 (30.97) | 110 (31.25) | 3.88 (0.94) | <0.05 | |
| f. People with history of STD | 4 (1.14) | 5 (1.42) | 131 (37.22) | 100 (28.41) | 111 (31.53) | 3.88 (0.92) | <0.05 | |
| g. Injection drug users | 4 (1.14) | 6 (1.7) | 134 (38.07) | 103 (29.26) | 105 (29.83) | 3.85 (0.91) | <0.05 | |
| h. Serodiscordant couples | 4 (1.14) | 2 (0.57) | 111 (31.53) | 114 (32.39) | 121 (34.38) | 3.98 (0.89) | <0.05 | |
| Q32. PrEP prescription remains suboptimal because... | ||||||||
| a. It is difficult to identify the target population | 4 (1.14) | 28 (7.95) | 225 (63.92) | 73 (20.74) | 22 (6.25) | 3.23 (0.73) | >0.05 | |
| b. Physicians have insufficient knowledge of PrEP | 4 (1.14) | 12 (3.41) | 190 (53.98) | 104 (29.55) | 42 (11.93) | 3.48 (0.79) | >0.05 | |
| c. There is lack of time to follow-up the patients | 1 (0.28) | 19 (5.4) | 203 (57.67) | 91 (25.85) | 38 (10.8) | 3.41 (0.77) | <0.05 | |
| d. There is lack of time to advise on the prevention of sexual risk behaviors | 6 (1.7) | 27 (7.67) | 196 (55.68) | 84 (23.86) | 39 (11.08) | 3.35 (0.84) | >0.05 | |
| e. There are not protocols or clinical practice guidelines | 2 (0.57) | 18 (5.11) | 202 (57.39) | 84 (23.86) | 46 (13.07) | 3.44 (0.8) | <0.05 | |
| f. Healthcare professionals do not discuss sexual risk behaviors with their patients | 4 (1.14) | 15 (4.26) | 207 (58.81) | 85 (24.15) | 41 (11.65) | 3.41 (0.79) | >0.05 | |
| Q33. PrEP demand is not higher because… | ||||||||
| a. Its existence is unknown | 4 (1.14) | 3 (0.85) | 106 (30.11) | 113 (32.1) | 126 (35.8) | 4.01 (0.89) | >0.05 | |
| b. People do not know where it can be obtained | 1 (0.28) | 6 (1.7) | 135 (38.35) | 104 (29.55) | 106 (30.11) | 3.88 (0.88) | >0.05 | |
| c. It could stigmatize people | 1 (0.28) | 10 (2.84) | 165 (46.88) | 98 (27.84) | 78 (22.16) | 3.69 (0.86) | <0.05 | |
| d. People do not know its efficacy | 1 (0.28) | 6 (1.7) | 137 (38.92) | 112 (31.82) | 96 (27.27) | 3.84 (0.86) | >0.05 | |
Answers were expressed on a five-point Likert scale (1 = strongly disagree to 5 = strongly agree). Statistical significance (p < 0.05) was determined by ANOVA and Student’s t-tests and Spearman’s correlation analysis. Abbreviations: HIV. Human immunodeficiency virus; PrEP. Pre-exposure prophylaxis; Q. Question; SD. Standard deviation; STDs. Sexually transmitted diseases.